-
New Data on Lilly’s Investigational Treatment Olomorasib at ESMO 2026 Show Durable First-Line Activity in KRAS G12C-Mutant Non-Small Cell Lung Cancer
NYSE: $LLY INDIANAPOLIS, Oct. 25, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at the 2026 European Society for Medical Oncology… Source: Read More
-
New Hope for ITP: Sovleplenib Receives FDA Orphan Drug Designation
A Significant Milestone for Rare Blood Disorders HUTCHMED (China) Limited has recently announced a major regulatory achievement for its investigational drug, sovleplenib. The U.S. Food and Drug Administration (FDA) has officially granted Orphan Drug Designation to sovleplenib for the treatment of primary immune thrombocytopenia (ITP). Understanding Primary Immune Thrombocytopenia Primary immune thrombocytopenia is a rare…
-
A New Frontier in Weight Loss: Retatrutide vs. Ozempic
NYSE: $LLY The Next Generation of Diabetes and Obesity Treatment A recent clinical trial has sent waves through the medical community, showcasing promising results for Eli Lilly’s experimental drug, retatrutide. As the landscape for metabolic health evolves, this new “triple-hormone” receptor agonist is showing potential to outperform current market leaders like Ozempic. Understanding the Clinical…
-
New Hope in Oncology: Izalontamab Brengitecan Shows Promise in Clinical Trials
NYSE: $BMY A Significant Milestone in Cancer Treatment Recent clinical trial data has brought encouraging news for patients fighting advanced cancers. The investigational therapy izalontamab brengitecan (Iza-Bren) has demonstrated significant efficacy, effectively doubling the median progression-free survival (PFS) in patients who have previously undergone multiple lines of treatment. Understanding the Impact For patients facing recurring…
-
Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer
NYSE: $MRK RAHWAY, N.J.–(BUSINESS WIRE) October 26, 2026 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 TroFuse-005 trial evaluating sacituzumab… Source: Read More
-
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
NASDAQ: $REGN TARRYTOWN, N.Y., Oct. 01, 2026 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (anti-GDF8/anti-myostatin) for its potential to prevent lean mass and… Source: Read More
-
A New Hope in Lung Cancer: FDA Grants Fast Track Designation for TRE-515 Combination
Accelerating Progress in NSCLC Treatment The landscape of lung cancer treatment continues to evolve, with the FDA recently granting Fast Track designation to the investigational therapeutic combination involving TRE-515. This designation is a significant milestone for patients fighting non-small cell lung cancer (NSCLC), particularly those whose tumors harbor specific genetic mutations. The Role of KRAS…
-
A Breakthrough in Alzheimer’s Treatment: Solengepras Shows Promise in Phase 3 Trials
New Hope for Alzheimer’s Patients Cerevance recently announced promising results from its Phase 3 ARISE clinical trial, marking a potential turning point in the treatment of Alzheimer’s disease. The study evaluated the efficacy and safety of solengepras, a novel once-daily oral medication designed to address the progression of cognitive decline. Meeting Primary Endpoints The ARISE…
-
Zealand Pharma Announces Positive Phase 2 ZUPREME-2 Topline Results for Amylin Analog Petrelintide in People with Overweight or Obesity and Type 2 Diabetes
NASDAQ: $ZEAL Copenhagen, Denmark, October 7, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announced positive topline results from the Phase 2 ZUPREME-2 trial… Source: Read More
-
Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)
NASDAQ: $IRON WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) — Disc Medicine, Inc. (NASDAQ:IRON), a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious… Source: Read More
-
EyePoint Pharmaceuticals Announces Positive Topline Results for DURAVYU in Wet AMD
NASDAQ: $EYPT A Major Milestone in Retinal Disease Treatment EyePoint Pharmaceuticals has officially announced the topline results from its LUCIA study, the second pivotal Phase 3 clinical trial evaluating the efficacy and safety of DURAVYU (vorolanib) for the treatment of wet age-related macular degeneration (wet AMD). Understanding the LUCIA Trial Results The LUCIA trial was…
-
XBiotech Reports Positive Phase II Results in Investigator-Sponsored TASKIN Trial
NASDAQ: $XBIT A New Milestone in Clinical Research XBiotech Inc. has announced positive final efficacy results from the investigator-sponsored TASKIN trial. This Phase II clinical study marks a significant step forward in the company’s efforts to evaluate the potential of its therapeutic candidates in a clinical setting. Understanding the TASKIN Trial The TASKIN trial was…
-
Novo’s CagriSema Was Associated with 25% Weight Loss on Average for Women in a Post Hoc Analysis of REDEFINE 1
PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Oct. 20, 2026 /PRNewswire/ — Today, Novo announced results from two post hoc analyses of the REDEFINE 1 trial presented at The Menopause Society 2026 Annual Meeting in San Diego. In an analysis of… Source: Read More
-
Breakthrough Results: Encaleret Shows Promise for Autosomal Dominant Hypocalcemia Type 1
NASDAQ: $BBIO A New Frontier in Treating ADH1 Recent results from the Phase 3 CALIBRATE trial have brought a wave of optimism for patients living with Autosomal Dominant Hypocalcemia Type 1 (ADH1). The trial evaluated the efficacy and safety of encaleret, an investigational therapy designed to address the underlying physiological challenges of this rare genetic…
-
AbbVie Presents Data for ABBV-466, a Novel Dual-Targeting Therapy Demonstrating Higher Endoscopic Remission Rates Than Either Anti-IL-23 or Anti-?4?7 Monotherapy in Moderate to Severe Crohn’s Disease
NYSE: $ABBV NORTH CHICAGO, Ill., Oct. 19, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that its investigational ABBV-466, a novel dual-targeting therapy against IL-23 p19 and integrin α4β7, demonstrated higher rates of endoscopic… Source: Read More
-
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Granted FDA Fast Track Designation for First-Line Advanced or Metastatic Biliary Tract Cancer
Nanjing, China — October 12, 2026 — Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track… Source: Read More
-
Blood-Pressure Drug Losartan May Activate Health-Promoting Brown Fat
October 14, 2026 — In a National Institutes of Health (NIH)-funded study, scientists have demonstrated that the drug losartan, commonly prescribed for high blood pressure, boosts brown adipose tissue activity in mice, enhancing their metabolism… Source: Read More
-
Marengo Therapeutics Receives Second U.S. FDA Fast Track Designation for Invikafusp Alfa, Expanding to a Tissue-Agnostic Indication Across Tumor Mutational Burden-High Solid Tumors That Progress After Prior Therapy, Including Checkpoint Inhibition
CAMBRIDGE, Mass., Oct. 15, 2026 /PRNewswire/ — Marengo Therapeutics Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), today announced that the U.S. Food and… Source: Read More
-
Merck Announces Promising One-Year Results for Remigromig in Phase 2b/3 Brunello Study
NYSE: $MRK A New Frontier in Autoimmune Research Merck has officially shared positive one-year results from its pivotal Phase 2b/3 Brunello clinical trial. The study is evaluating the safety and efficacy of remigromig, an investigational anti-PD-1 therapy, specifically targeting patients living with moderate-to-severe systemic lupus erythematosus (SLE). Understanding the Brunello Study The Brunello trial is…
-
Promising Progress: Efzimfotase Alfa Shows Improvement in Hypophosphatasia Treatment
A New Frontier in HPP Research Recent clinical trial findings have shed light on a potential breakthrough for patients living with hypophosphatasia (HPP), a rare and serious genetic disorder. Data recently released regarding efzimfotase alfa—an investigational enzyme replacement therapy—suggests a meaningful step forward in managing the physical limitations associated with this condition. Understanding the Clinical…
-
New Hope on the Horizon: Bristol Myers Squibb Launches Phase 3 ALOFT Trial for IPF
NYSE: $BMY A New Frontier in Pulmonary Research The fight against Idiopathic Pulmonary Fibrosis (IPF), a progressive and chronic lung disease, has reached a significant milestone. Bristol Myers Squibb has officially announced the initiation of the Phase 3 ALOFT clinical trial, a critical step in evaluating the efficacy and safety of a potential new treatment:…
-
A New Hope for Alopecia Areata: FDA Breakthrough Designation for Cinainu
A Major Milestone in Hair Loss Treatment There is promising news for individuals living with alopecia areata. Legacy Healthcare has officially announced that their investigational drug, Cinainu, has received FDA Breakthrough Therapy Designation for the treatment of alopecia areata in adults. Understanding the Significance The FDA’s Breakthrough Therapy Designation is a vital step in the…
-
New Hope in Neuroendocrine Tumors: Bristol Myers Squibb Announces Positive Phase 3 Results for RYZ101
NYSE: $BMY A Major Milestone in Cancer Research Bristol Myers Squibb (BMS) has officially announced positive topline results from an interim analysis of the Phase 3 ACTION-1 clinical trial. This study evaluated the safety and efficacy of RYZ101 (lutetium Lu 177 dotatate) in patients suffering from gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Understanding the ACTION-1 Trial The…